Sandostatin Octreotide Acetate Injection

1. Indications and Usage
Acromegaly: Indicated for control of symptoms and reduction of growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels in patients who do not respond adequately to or are unsuitable for surgery/radiotherapy.
Gastroenteropancreatic (GEP) Neuroendocrine Tumors: Used to relieve symptoms associated with functional GEP tumors, such as carcinoid tumors and VIPomas.
Esophageal Variceal Hemorrhage: Indicated for the emergency treatment of bleeding due to esophageal varices in patients with liver cirrhosis, usually in conjunction with specific endoscopic treatments.
Prevention of Postoperative Complications: Used for the prevention of complications following pancreatic surgery.
2. Dosage and Administration
Acromegaly: The initial dose is typically 0.05 to 0.1 mg subcutaneously every 8 hours. The dose can be gradually increased based on clinical response and tolerance to a maximum of 1.5 mg per day.
GEP Neuroendocrine Tumors: The initial dose is usually 0.05 mg subcutaneously once or twice daily. The dose can be titrated up to 0.2 mg three times daily.
Esophageal Variceal Hemorrhage: A 0.025 mg/hour continuous intravenous infusion is recommended for up to 5 days.
Postoperative Pancreatic Complications: 0.1 mg subcutaneously three times daily for 7 days, with the first dose administered at least 1 hour before surgery.
Administration: The injection should be administered subcutaneously or intravenously as indicated.
3. Mechanism of Action
Somatostatin Receptor Agonism: Octreotide selectively binds to and activates somatostatin receptors (primarily subtypes 2 and 5) on cell membranes.
Hormonal Inhibition: This binding inhibits the secretion of several hormones, including growth hormone (GH), insulin, glucagon, gastrin, and vasoactive intestinal peptide (VIP).
4. Safety and Warnings
Biliary Tract Disorders: Long-term use may lead to gallstone formation (cholelithiasis) and biliary sludge; periodic gallbladder ultrasound examinations are recommended.
Glucose Metabolism: The drug can cause disturbances in glucose metabolism, including both hyperglycemia and hypoglycemia.
Cardiac Effects: ECG changes, such as QT interval prolongation, have been observed in patients with acromegaly and carcinoid syndrome.
Renal/Hepatic Impairment: Dosage adjustments may be necessary for patients with severe hepatic impairment due to prolonged drug half-life.
5. Adverse Reactions and Clinical Research
Gastrointestinal: The most common adverse reactions include abdominal pain, nausea, diarrhea, and flatulence.
Injection Site Reactions: Pain, stinging, or burning sensations at the injection site are frequently reported.
Biliary Disorders: Cholelithiasis and cholelithiasis-related pancreatitis may occur with long-term administration.
Clinical Research: Pivotal trials have demonstrated that octreotide effectively reduces GH levels and improves symptoms in acromegaly and carcinoid syndrome patients.
6. Drug Interactions
Cyclosporine: Octreotide may decrease the intestinal absorption of cyclosporine.
Cimetidine: The absorption of cimetidine may be delayed.
Insulin and Oral Hypoglycemics: Dose adjustments for antidiabetic medications may be required due to the drug’s effect on insulin secretion.
7. Pharmaceutical Information
Active Ingredient: Octreotide Acetate.
Excipients: Lactic acid, mannitol, and water for injection.
Appearance: A clear, colorless liquid.
Storage: Store protected from light in a cool place (2–10°C).